MyoKardia

MyoKardia, Inc. is a clinical-stage biopharmaceutical company based in Brisbane, California, specializing in the discovery, development, and commercialization of targeted therapies for rare cardiovascular diseases. Founded in 2012, the company focuses on heritable cardiomyopathies and genetically-driven heart failure stemming from biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently undergoing Phase III clinical trials for hypertrophic cardiomyopathy (HCM). Additionally, MyoKardia is developing Danicamtiv, which has completed Phase I and IIa trials for dilated cardiomyopathy, alongside several preclinical programs targeting related cardiovascular conditions. As of November 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.